NDC product
AsperFlex MAX
NDC 71399-4453 · Akron Pharma Inc.
Key facts
| Product NDC | 71399-4453 |
|---|---|
| Proprietary name | AsperFlex MAX |
| Nonproprietary name | Lidocaine 4% with Menthol 1% |
| Substances | LIDOCAINE, MENTHOL |
| Dosage form | PATCH |
| Route | TOPICAL |
| Labeler | Akron Pharma Inc. |
| Product type | HUMAN OTC DRUG |
| Marketing category | OTC MONOGRAPH DRUG |
| Application number | M017 |
| Pharmacologic classes | Amide Local Anesthetic [EPC], Amides [CS], Antiarrhythmic [EPC], Local Anesthesia [PE] |
| Marketing start | Nov 4, 2021 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: